A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

← catalyst calendar

NCT05259839 · readout ≤ 2,599 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

283actual

Sites

Countries

Australia, Germany, Italy +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-10-20

actual

When the study began enrolling

Primary completion

Sep 2033

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2033

estimated

The whole study's end, after follow-up

First posted

2022-03-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Relapsed/Refractory Multiple Myeloma

Interventions

Drug: Etentamig — also filed as ABBV-383
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Daratumumab

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Dose Limiting Toxicities (DLT) of Etentamig

measured Up to approximately 28 Days

Number of Participants with Adverse Events (AEs)

measured Up to Approximately 3 Years

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed